A Study of Itacitinib in Combination With Low-Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Participants With Myelofibrosis

NCT03144687 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

MPN (Myeloproliferative Neoplasms)

Interventions

DRUG: Itacitinib
DRUG: Ruxolitinib

Sponsor

Incyte Corporation